ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) announced that Waterbury Pulmonary Associates Research has joined the pilot clinical study of Biomoda’s CyPath® diagnostic assay. Waterbury Pulmonary Associates Research is enrolling participants for the positive control group, patients diagnosed with lung cancer who have not yet started treatment. Based in Waterbury, CT, Waterbury Pulmonary Associates Research is the clinical research arm of a pulmonary and critical care practice.
“The addition of Waterbury Pulmonary as an enrollment site for the positive control group should expedite patient recruitment and the completion of our pilot study,” Biomoda Chief Executive Officer Maria Zannes said. “Completing the pilot study is our top priority.”
Dr. David G. Hill, director of clinical research at Waterbury Pulmonary, will serve as the local Principal Investigator (PI) for Biomoda's study. Board certified in critical care, pulmonary and internal medicine, Dr. Hill is also affiliated with the Yale University School of Medicine and its teaching hospitals. The protocol for Waterbury Pulmonary’s participation in the Biomoda study was approved by the Biomedical Research Alliance of New York (BRANY) (www.brany.com) Institutional Review Board.
Dr. Thomas L. Bauer, national PI of the Biomoda study, will continue to oversee collection of samples in the positive control group at the Helen F. Graham Cancer Center, Christiana Care Health System, in Newark, DE, where he is chief of thoracic surgery.
Biomoda’s CyPath® assay is based on a porphyrin compound that binds to cancer cells and fluoresces under specific frequencies of light. Participants in the pilot clinical study provide deep-lung sputum samples to be labeled with the CyPath® solution and viewed under fluorescent microscopy. Biomoda is seeking Food and Drug Administration (FDA) approval of its screening technology as a Class III medical device. Pending FDA approval, CyPath® is for investigational use only.
Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.
About Waterbury Pulmonary Associates Research
Waterbury Pulmonary Associates Research is the active clinical research arm of a large single specialty private practice pulmonary and critical care group. Its mission is to provide excellent clinical research recruitment and study performance while enhancing the care of patients and research subjects. Waterbury Pulmonary’s researchers are all Yale University faculty members and attending medical staff at two Yale University-affiliated teaching hospitals.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, which are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.
Julie Anne Overton, 505-577-0918
KEYWORDS: United States North America Connecticut New Mexico
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Hospitals Medical Devices Oncology General Health